Screener
Immunovant, Inc. IMVT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Accrued expenses | 96,634 | 50,748 |
| Current portion of operating lease liabilities | 72 | 98 |
| Due to Roivant Sciences Ltd. | 175 | 273 |
| Total current liabilities | 104,422 | 68,775 |
| Total liabilities | 104,422 | 68,775 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s total current liabilities?
- Immunovant, Inc. (IMVT) reported total current liabilities of $104.42M in Q1 2026.
- How has Immunovant, Inc.'s total current liabilities changed year-over-year?
- Immunovant, Inc.'s total current liabilities increased by 51.8% year-over-year, from $68.78M to $104.42M.
- What is the long-term trend for Immunovant, Inc.'s total current liabilities?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total current liabilities has grown at a 40.9% compound annual growth rate (CAGR), from $18.77M to $104.42M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Immunovant, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude